当前位置: X-MOL 学术Lancet Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Attrition in metastatic breast cancer: a metric to be reported in randomised clinical trials?
The Lancet Oncology ( IF 51.1 ) Pub Date : 2020-01-01 , DOI: 10.1016/s1470-2045(19)30792-2
Imperia Nuzzolese 1 , Filippo Montemurro 2
Affiliation  

Breast cancer remains an incurable disease, causing about 630 000 deaths in 2018 worldwide. A better understanding of the underlying biology and the availability of more active drugs have substantially extended life expectancy in some subsets of patients with metastatic breast cancer. New drug approvals are dependent on randomised clinical trials that test new treatments head-to-head against standards of care. Although this methodology is pivotal in clinical research, in practice, patients with metastatic breast cancer receive different treatments sequentially across multiple progressions of their disease. Due to a paucity of studies that specifically address treatment sequencing, guidelines recommend first and further lines of treatment on the basis of the results of separate randomised trials specifically conducted in each line of therapy. With the growing number of therapeutic options with overlapping indications, treatment sequencing is becoming a critical issue both in research and clinical practice.

中文翻译:

转移性乳腺癌的流失:一项在随机临床试验中报告的指标?

乳腺癌仍然是无法治愈的疾病,2018年在全世界造成约63万例死亡。对潜在生物学的更好理解和更多活性药物的可用性已大大延长了转移性乳腺癌患者某些亚组的预期寿命。新药的批准取决于随机的临床试验,这些临床试验与护理标准相提并论。尽管这种方法在临床研究中至关重要,但实际上,转移性乳腺癌患者会在疾病的多个进程中相继接受不同的治疗。由于缺乏专门针对治疗顺序的研究,因此指南根据在每种治疗方案中专门进行的单独随机试验的结果,建议了第一和进一步的治疗方案。
更新日期:2020-01-04
down
wechat
bug